Journey Medical Insider raises $187,000 with $520,000 investment

Journey Medical Co., Ltd. (NASDAQ:DERM) insiders who have acquired shares in the last twelve months can probably afford to ignore the recent 16% share price decline. Taking into account the recent losses, his US$520,000 worth of shares they bought is now worth US$708,000, suggesting a good return on investment.

Insider trading isn’t the most important thing when it comes to long-term investing, but logically you should pay some attention to whether insiders are buying or selling shares.

Check out our latest analysis for Journey Medical.

Journey Medical Insider Trading Over the Past Year

Executive Chairman Lindsey Rosenwald has made the biggest insider purchase in the past 12 months. In this one trade of hers, US$223,000 worth of shares traded at US$2.23 per share. We expect a buy, but this purchase was made well below her current price of $3.47. The stock was purchased at a lower price, so this particular purchase doesn’t tell us much about how insiders feel about the current share price.

In the last twelve months, insiders bought 204,040 shares for US$521,000. However, they sold 75.91 thousand shares for USD 128 thousand. In total, Journey Medical insiders bought more products than they sold in the last year. The average purchase price was approximately $2.55. In my opinion, it’s good to see insiders have invested their own money in the company. However, it should be noted that the investment was made at a price well below today’s stock price. The graph below shows insider transactions (by companies and individuals) over the last year. You can click on the graph below to see the exact details of each insider transaction.

Journey Medical isn’t the only stock that insiders are buying.So take a look at this free A list of growing companies with insider buying.

Are Journey Medical insiders buying or selling?

We’ve seen a bit of insider selling in Journey Medical over the past three months. Interim CFO and Corporate Controller Joseph Benesch only realized a stock sale gain of $92,000 during the period. A lack of insider sales or recent buyers is not a good thing. However, the sales volume is very small, so there is nothing to worry about.

story continues

Insider ownership

I like to see how many shares a company’s insiders own in a company, as it can tell us how well aligned a company is with its insiders. Typically, the higher the insider ownership, the more likely it is that insiders are incentivized to build the company for the long term. According to our data, it seems that Journey Medical insiders own 12% of the company, worth about US$7.7m. While it’s better than nothing, we’re not very impressed with these holdings.

So what does Journey’s medical insider trading show?

There has been no insider buying over the past three months, but there has been some selling. But given the modest sales, we’re not worried. However, insiders have indicated that interest in the stock has increased over the last year. The trade is fine, but it would be even more encouraging if Journey Medical insiders bought more shares in the company. So while these insider transactions can help us form a theory about the stock, it’s also worth knowing what risks this company faces. During our analysis, we found that Journey Medical: 4 warning signs It is unwise to ignore these.

of course, You may find a great investment if you look elsewhere. So take a look at this free List of interesting companies.

For the purposes of this article, insiders are individuals who report their transactions to the relevant regulatory body. The Company currently only accounts for open market transactions and private dispositions of direct profits, and does not account for derivative transactions or indirect profits.

Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.